کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3398751 | 1222316 | 2008 | 4 صفحه PDF | دانلود رایگان |
ABSTRACTTherapy of infections caused by extended-spectrum β-lactamase (ESBL)-producing bacteria with an antimicrobial to which they are resistant results in treatment failure, higher cost and increased mortality. The CLSI recommends reporting ESBL-producing strains of Escherichia coli, Klebsiella spp. and Proteus spp. as resistant to all penicillin, true cephalosporin and monobactam antimicrobials, but as susceptible to β-lactam-β-lactamase inhibitor combinations, including piperacillin–tazobactam, when they test as such. Current literature supports the action of piperacillin–tazobactam against susceptible strains of ESBL-producing bacteria based on the structure–activity relationship between inhibitors and the ESBLs, as well as on recent clinical outcome studies.
Journal: Clinical Microbiology and Infection - Volume 14, Supplement 1, January 2008, Pages 181–184